Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19
Descripción del Articulo
Objective: This study analyzed the phenotypic and antifungal resistance profile of fungi isolated from pulmonary infections in critically patients with COVID-19. Materials and methods: Information was obtained on fungal strains isolated at the National Reference Laboratory of Mycology (LRNM) from ho...
| Autores: | , , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2025 |
| Institución: | Universidad de Ciencias y Humanidades |
| Repositorio: | Health care & global health |
| Lenguaje: | español |
| OAI Identifier: | oai:ojs.openhgh.org:article/305 |
| Enlace del recurso: | http://revista.uch.edu.pe/index.php/hgh/article/view/305 |
| Nivel de acceso: | acceso abierto |
| id |
REVUCH_9377a8cbb74874ddb021d7308adbf25b |
|---|---|
| oai_identifier_str |
oai:ojs.openhgh.org:article/305 |
| network_acronym_str |
REVUCH |
| network_name_str |
Health care & global health |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19 Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19: Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19 Resistência antifúngica e variabilidade fenotípica em micoses pulmonares em pacientes críticos com COVID-19: Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19 |
| title |
Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19 |
| spellingShingle |
Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19 Paredes-Gago, Rolando |
| title_short |
Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19 |
| title_full |
Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19 |
| title_fullStr |
Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19 |
| title_full_unstemmed |
Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19 |
| title_sort |
Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19 |
| dc.creator.none.fl_str_mv |
Paredes-Gago, Rolando Valencia-Vásquez, Pedro Gustavo Úrcia-Ausejo, Flor Cecilia Escalante-Maldonado, Oscar Roberto Ayala-Mendívil, Ronald Espíritu |
| author |
Paredes-Gago, Rolando |
| author_facet |
Paredes-Gago, Rolando Valencia-Vásquez, Pedro Gustavo Úrcia-Ausejo, Flor Cecilia Escalante-Maldonado, Oscar Roberto Ayala-Mendívil, Ronald Espíritu |
| author_role |
author |
| author2 |
Valencia-Vásquez, Pedro Gustavo Úrcia-Ausejo, Flor Cecilia Escalante-Maldonado, Oscar Roberto Ayala-Mendívil, Ronald Espíritu |
| author2_role |
author author author author |
| description |
Objective: This study analyzed the phenotypic and antifungal resistance profile of fungi isolated from pulmonary infections in critically patients with COVID-19. Materials and methods: Information was obtained on fungal strains isolated at the National Reference Laboratory of Mycology (LRNM) from hospitalized patients with COVID-19. The Fungi were identified by mass spectrometry (MALDI-TOF) and molecular techniques, classifying phenotypes and evaluating antifungal sensitivity according to the Clinical & Laboratory Standards Institute (CLSI). Antifungals such as anidulafungin, micafungin, caspofungin, voriconazole, fluconazole, itraconazole and amphotericin B were tested. Results: In yeasts, Candida albicans was the predominant species (73,5%), followed by Candida tropicalis (19,3%). In filamentous fungi, Aspergillus fumigatus was the most frequent (78,3%), followed by Aspergillus terreus (17,4%). Most strains of Candida albicans were sensitive to antifungals, with a small percentage resistant to fluconazole. In Aspergillus fumigatus, voriconazole was effective in 77.8% of cases, with some strains categorized as intermediate or resistant. In general, Candida and Aspergillus strains showed sensitivity to echinocandins and azoles, with minimal resistance. The variability in the minimum inhibitory concentrations of the different species was reflected in the data obtained. Conclusions: Candida albicans and Aspergillus fumigatus were the predominant fungi, with general sensitivity to echinocandins and azoles, although some resistant strains were observed, especially to fluconazole and voriconazole. These findings highlight the importance of accurate diagnosis and appropriate therapeutic management in fungal infections, underlining the need to customize treatments according to the species and its sensitivity profile. Keywords: COVID-19; Lung Diseases, Fungal; Drug Resistance, Fungal; Aspergillus (Source: MeSH, NLM). |
| publishDate |
2025 |
| dc.date.none.fl_str_mv |
2025-03-06 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://revista.uch.edu.pe/index.php/hgh/article/view/305 |
| url |
http://revista.uch.edu.pe/index.php/hgh/article/view/305 |
| dc.language.none.fl_str_mv |
spa |
| language |
spa |
| dc.relation.none.fl_str_mv |
http://revista.uch.edu.pe/index.php/hgh/article/view/305/182 http://revista.uch.edu.pe/index.php/hgh/article/view/305/216 |
| dc.rights.none.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf text/xml |
| dc.publisher.none.fl_str_mv |
Universidad de Ciencias y Humanidades (UCH) |
| publisher.none.fl_str_mv |
Universidad de Ciencias y Humanidades (UCH) |
| dc.source.none.fl_str_mv |
Peruvian Journal of Health Care and Global Health; Vol. 9 No. 1 (2025); 6-14 Peruvian Journal of Health Care and Global Health; Vol. 9 Núm. 1 (2025); 6-14 Peruvian Journal of Health Care and Global Health; v. 9 n. 1 (2025); 6-14 2522-7270 10.22258/hgh.2025.91 reponame:Health care & global health instname:Universidad de Ciencias y Humanidades instacron:UCH |
| instname_str |
Universidad de Ciencias y Humanidades |
| instacron_str |
UCH |
| institution |
UCH |
| reponame_str |
Health care & global health |
| collection |
Health care & global health |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1846792766813634560 |
| spelling |
Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19: Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19Resistencia antifúngica y variabilidad fenotípica en micosis pulmonares en pacientes críticos con COVID-19: Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19Resistência antifúngica e variabilidade fenotípica em micoses pulmonares em pacientes críticos com COVID-19: Antifungal resistance and phenotypic variability in pulmonary mycoses in critically ill patients with COVID-19Paredes-Gago, RolandoValencia-Vásquez, Pedro GustavoÚrcia-Ausejo, Flor CeciliaEscalante-Maldonado, Oscar RobertoAyala-Mendívil, Ronald EspírituObjective: This study analyzed the phenotypic and antifungal resistance profile of fungi isolated from pulmonary infections in critically patients with COVID-19. Materials and methods: Information was obtained on fungal strains isolated at the National Reference Laboratory of Mycology (LRNM) from hospitalized patients with COVID-19. The Fungi were identified by mass spectrometry (MALDI-TOF) and molecular techniques, classifying phenotypes and evaluating antifungal sensitivity according to the Clinical & Laboratory Standards Institute (CLSI). Antifungals such as anidulafungin, micafungin, caspofungin, voriconazole, fluconazole, itraconazole and amphotericin B were tested. Results: In yeasts, Candida albicans was the predominant species (73,5%), followed by Candida tropicalis (19,3%). In filamentous fungi, Aspergillus fumigatus was the most frequent (78,3%), followed by Aspergillus terreus (17,4%). Most strains of Candida albicans were sensitive to antifungals, with a small percentage resistant to fluconazole. In Aspergillus fumigatus, voriconazole was effective in 77.8% of cases, with some strains categorized as intermediate or resistant. In general, Candida and Aspergillus strains showed sensitivity to echinocandins and azoles, with minimal resistance. The variability in the minimum inhibitory concentrations of the different species was reflected in the data obtained. Conclusions: Candida albicans and Aspergillus fumigatus were the predominant fungi, with general sensitivity to echinocandins and azoles, although some resistant strains were observed, especially to fluconazole and voriconazole. These findings highlight the importance of accurate diagnosis and appropriate therapeutic management in fungal infections, underlining the need to customize treatments according to the species and its sensitivity profile. Keywords: COVID-19; Lung Diseases, Fungal; Drug Resistance, Fungal; Aspergillus (Source: MeSH, NLM).Objetivo: Este estudio analizó el perfil fenotípico y de resistencia antifúngica en hongos aislados de infecciones pulmonares en pacientes críticos con COVID-19. Materiales y métodos: Se obtuvo información sobre cepas fúngicas aisladas en el Laboratorio de Referencia Nacional de Micología (LRNM) de pacientes hospitalizados con COVID-19. Los hongos fueron identificados mediante espectrometría de masas (MALDI-TOF) y técnicas moleculares, clasificando los fenotipos y evaluando la sensibilidad a antifúngicos conforme a los estándares del Instituto de estándares clínicos y de laboratorio (CLSI). Se probaron antifúngicos como anidulafungina, micafungina, caspofungina, voriconazol, fluconazol, itraconazol y anfotericina B. Resultados: En levaduras, Candida albicans fue la especie predominante (73,5%), seguida de Candida tropicalis (19,3%). En hongos filamentosos, Aspergillus fumigatus fue el más frecuente (78,3%), seguido de Aspergillus terreus (17,4%). La mayoría de las cepas de Candida albicans fueron sensibles a los antifúngicos, con un pequeño porcentaje resistente al fluconazol. En Aspergillus fumigatus, voriconazol fue eficaz en el 77,8% de los casos, con algunas cepas categorizadas como intermedias o resistentes. En general, las cepas de Candida y Aspergillus mostraron sensibilidad a equinocandinas y azoles, con resistencia mínima, La variabilidad en las concentraciones mínimas inhibidoras de las distintas especies se reflejó en los datos obtenidos. Conclusiones: Candida albicans y Aspergillus fumigatus fueron los hongos predominantes, con sensibilidad general a equinocandinas y azoles, aunque se observaron algunas cepas resistentes, especialmente a fluconazol y voriconazol. Estos hallazgos resaltan la importancia de un diagnóstico preciso y una gestión terapéutica adecuada en infecciones fúngicas, subrayando la necesidad de personalizar los tratamientos según la especie y su perfil de sensibilidad. Palabras clave: COVID-19; Micosis Pulmonar; Farmacorresistencia Fúngica; Aspergillus (Fuente: DeCS, BIREME).Objetivo: Este estudo analisou o perfil fenotípico e a resistência antifúngica de fungos isolados de infecções pulmonares em pacientes críticos com COVID-19. Materiais e métodos: Foram obtidas informações sobre cepas fúngicas isoladas no Laboratório de Referência Nacional de Micologia (LRNM) de pacientes hospitalizados com COVID-19. Os fungos foram identificados por espectrometria de massas (MALDI-TOF) e técnicas moleculares. Os fenótipos foram classificados e a sensibilidade aos antifúngicos foi avaliada de acordo com os padrões do Clinical & Laboratory Standards Institute (CLSI). Foram testados antifúngicos como anidulafungina, micafungina, caspofungina, voriconazol, fluconazol, itraconazol e anfotericina B. Resultados: Entre as leveduras, Candida albicans foi a espécie predominante (73,5%), seguida por Candida tropicalis (19,3%). Entre os fungos filamentosos, Aspergillus fumigatus foi o mais frequente (78,3%), seguido por Aspergillus terreus (17,4%). A maioria das cepas de Candida albicans foi sensível aos antifúngicos, com um pequeno percentual resistente ao fluconazol. Em Aspergillus fumigatus, o voriconazol foi eficaz em 77,8% dos casos, com algumas cepas classificadas como intermediárias ou resistentes. No geral, as cepas de Candida e Aspergillus apresentaram sensibilidade às equinocandinas e azóis, com resistência mínima. A variabilidade nas concentrações mínimas inibitórias entre espécies foi refletida nos dados obtidos. Conclusões: Candida albicans e Aspergillus fumigatus foram os fungos predominantes, com sensibilidade geral às equinocandinas e azóis. No entanto, algumas cepas resistentes foram identificadas, especialmente ao fluconazol e voriconazol. Esses achados destacam a importância de um diagnóstico preciso e de um manejo terapêutico adequado em infecções fúngicas, enfatizando a necessidade de personalizar os tratamentos de acordo com a espécie e seu perfil de sensibilidade.Universidad de Ciencias y Humanidades (UCH)2025-03-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/xmlhttp://revista.uch.edu.pe/index.php/hgh/article/view/305Peruvian Journal of Health Care and Global Health; Vol. 9 No. 1 (2025); 6-14Peruvian Journal of Health Care and Global Health; Vol. 9 Núm. 1 (2025); 6-14Peruvian Journal of Health Care and Global Health; v. 9 n. 1 (2025); 6-142522-727010.22258/hgh.2025.91reponame:Health care & global healthinstname:Universidad de Ciencias y Humanidadesinstacron:UCHspahttp://revista.uch.edu.pe/index.php/hgh/article/view/305/182http://revista.uch.edu.pe/index.php/hgh/article/view/305/216Derechos de autor 2025 Rolando Paredes-Gago, Pedro Gustavo Valencia-Vásquez, Flor Cecilia Úrcia-Ausejo, Oscar Roberto Escalante-Maldonado, Ronald Espíritu Ayala-Mendívilhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:ojs.openhgh.org:article/3052025-08-05T03:02:50Z |
| score |
12.791238 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).